Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Eli Lilly and Company (LLY)

NYSE
Currency in USD
Disclaimer
735.47
+10.60(+1.46%)
Real-time Data

LLY Comments

Just look at this multi year charts . Amazing for longs . Time for sellers is coming , speed down will be much more agressive for sure
Last pump before earnings . Next add 750$
odd movement pre earnings tmw, whats up
Jeffries want’s to unload on retail, so posted a buy upgrade to $768
 Thx, seems like a pretty large jump based on one analyst, tmw should be interesting, cheers and happy trading
Adding more puts 705 TP 505
Short 700$
The reason why people don't make it in crypto is because they haven't made a good decision towards their investments, this man has been the only one that has helped me out in some of my trade which has really helped me alot I pray God bless him and your family write him in wAsPP +31612574318) 8487545464848487675787675454342424544884889767548454545454245454545466464642454548454545454545484546454372757578767875545578757845464542727643464878797645464242434348787676457655434575787976765656485755787876454875766464
Short 666
Does DONANEMAB can be approuve from FDA with only one phase 3 study,phase 2 was reject because less than 100 peoples at the end study.And medicare ,Will they pay with one study???
+700 on the way
Heading to 700$ area . Thia bubble still has some way to go but definetely on the top list to short it . Waiting close to 700 to start building short position
cred că e o idee buna de short in curând dar prudent inca nu m as grabi
as zice că tesla e mai sigura do asta de vedere
Tesla e mai riscanta pentru short . Nu as risca pe tesla . Dar mamutul asta se va prabusii la un moment dat e clar
The trend has contributed to a recent dip in U.S. prescriptions, an executive at the Danish drugmaker said at an investor conference last month. Out of 24 diabetes patients contacted by Reuters on Reddit, 13 reported recent problems getting their health plans to cover Ozempic or Mounjaro, a similar drug sold by Eli Lilly (NYSE:LLY). - Reuters
you made a lot of investors to buy MRNA , while it was peaking to all time high of 500 and look where it is now ? when everyone loses weight, they will stop buying medicines for blood pressure،, diabetes and dementia. this kill their own other business. also, if many people start getting thyroid cancers and pancreatitis, the downhill spiral will start.
yeap, there are many uncertainties, and a lot can go wrong. the best scenario is priced in for now, when that narrative changes the stock tanks.
my view is that at this level you start trimming your position with each move up
🏆
Just an advice don't short this animal, I'm very serious
Totally agree, one of my core holdings, next big deal will be Alheimers research, possible game changer for stock and more importantly control of this awful disease, happy investing!
What we need here is a stock split, or an increase in dividend payouts
Hope to see close to 700$ so i can short as much as i can
lol... you are a forum regular which probably doesn't even have a pot to piss in wasting everyday posting negativity in investment forums
sweeeeet!
700 eoy
yes, and will short it
why going down ? to push up on earning ?
waterfall
Rising and falling stock, best for traders
Split soon?
Has the final guidance of NICE(British) been published? doees anyone knows?
I'd shorts but I need a serious catalyst. waiting patiently
Next add at 660$ , doubling position there
Adding shorts
...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.